Baxdrostat met primary, secondary endpoints in BaxHTN Phase III trial in patients with… EP News Bureau Jul 24, 2025 Baxdrostat is a potential first-in-class, highly selective aldosterone synthase inhibitor that targets the hormone driving…
Researchers identify rise in Guillain-Barre syndrome following AstraZeneca vaccine IANS Jun 2, 2022 Researchers at the University College London (UCL) said they are yet to understand the cause of the link
